Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11344332 | 0.87 | GABRA1 (0.37) | GABRA1GABRB2NISCHADRA2AADRA2B | |
| SCHEMBL2962387 | 0.84 | KMT2A (0.47) | CYP1A2LMNACYP3A4TSHRCA1 | |
| SCHEMBL11012886 | 0.84 | KMT2A (0.47) | CYP1A2LMNACYP3A4TSHRCA1 | |
| SCHEMBL8245039 | 0.82 | NISCH (0.49) | GABRA1GABRB2NISCHADRA2AADRA2B | |
| SCHEMBL28120983 | 0.80 | KMT2A (0.42) | ADRA2AADRA2CLMNACYP3A4TSHR | |
| SCHEMBL6446470 | 0.80 | LMNA (0.44) | GABRA1GABRB2NISCHADRA2AADRA2B | |
| SCHEMBL34024 | 0.80 | TSHR (0.41) | LMNATSHRALDH1A1MEN1KMT2A | |
| Hydrogen Sulfide SCHEMBL27992927 | 0.80 | NISCH (0.47) | GABRA1GABRB2NISCHADRA2AADRA2B | |
| SCHEMBL2737257 | 0.78 | NISCH (0.46) | GABRA1GABRB2NISCHADRA2AADRA2B | |
| SCHEMBL11951614 | 0.78 | NISCH (0.46) | GABRA1GABRB2NISCHADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409638-A1 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF | MEDICON PHARMACEUTICALS INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20190307780-A1 | Anti-Inflammatory Compounds and Uses Thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | US | disclosed |
| US-9447026-B2 | Bicyclic analgesic compounds | KALYRA PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160016892-A1 | BICYCLIC ANALGESIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20090163621-A1 | Process for improving color of polycondensates | SIMON DIRK | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307780-A1 | Anti-Inflammatory Compounds and Uses Thereof | TNF, NFKBIA, IL6 | GABRA1 2983/4885GABRB2 1809/4885NISCH 1577/4885 |
| US-20160016892-A1 | BICYCLIC ANALGESIC COMPOUNDS | OPRK1, OPRL1, OPRM1 | GABRA1 296/4885GABRB2 234/4885NISCH 594/4885 |
| US-20220409638-A1 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF | TNF, NFKBIA, IL6 | GABRA1 2983/4885GABRB2 1809/4885NISCH 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.